|Datasheet||Specific References||Reviews||Related Products||Protocols|
|ORF Clone of Macaca fascicularis (Crab-eating macaque) (Cynomolgus monkey) interferon (alpha, beta and omega) receptor 2 DNA.|
|Identical with NM_001032943.1 [ Macaca mulatta (Rhesus monkey) ]: 305 C/T, 1196 C/A, 1223 A/G, 1432 A/G, 1503 G/C resulting in the amino acid Thr substitution by Ile, Ala substitution by Glu, Glu substitution by Gly, Thr substitution by Ala, Glu substitution by Asp and 672 C/T, 762 G/A not causing the amino acid variation. Please check the sequence information before order.|
|Whatman FTA elute card (Cat: WB120410) contains 5-10 μg of plasmid.|
|The Whatman FTA elute card can be stored at room temperature for three months under dry condition.|
The pGEM-T is 3kb in length, and contains the amplicin resistance gene, conferring selection of the plasmid in E. coli, and the ori site which is the bacterial origin of replication. The plasmid has multiple cloning sites as shown below. The coding sequence was inserted by TA cloning. Many E. coli strains are suitable for the propagation of this vector including JM109, DH5α and TOP10.
The coding sequence can be easily obtained by digesting the vector with proper restriction enzyme(s). The coding sequence can also be amplified by PCR with M13 primers, or primer pair SP6 and T7.
|Cynomolgus monkey IFNAR2 Gene cDNA Clone (full-length ORF Clone), expression ready, FLAG-tagged||CG90112-G-F|
|Cynomolgus monkey IFNAR2 Gene cDNA Clone (full-length ORF Clone), expression ready, His-tagged||CG90112-G-H|
|Cynomolgus monkey IFNAR2 Gene cDNA Clone (full-length ORF Clone), expression ready, Myc-tagged||CG90112-G-M|
|Cynomolgus monkey IFNAR2 Gene cDNA Clone (full-length ORF Clone), expression ready, untagged||CG90112-G-N|
|Cynomolgus monkey IFNAR2 Gene cDNA Clone (full-length ORF Clone), expression ready, HA-tagged||CG90112-G-Y|
|Product name||Product name|
Interferon-alpha/beta receptor beta chain (IFNAR2) is a type I membrane protein that forms one of the two chains of a receptor for interferons alpha and beta. Binding and activation of the receptor stimulates Janus protein kinases, which in turn phosphorylate several proteins, including STAT1 and STAT2. Initial cell-surface IFNAR2 expression at diagnosis assessed by flow cytometry widely distributed but showed overall significantly higher expression in CML patients when compared with normal controls. In 15 fresh patients who subsequently received IFNα therapy, IFNAR2 expression at diagnosis was significantly higher in cytogenetic good responders than in poor responders. Down-regulation of IFNAR2 expression during IFNα therapy was observed only in good responders but not in poor responders. The encoded protein also functions as an antiviral factor. IFNAR2 may associate with IFNAR1 to form the type I interferon receptor. This protein serves as a receptor for interferons alpha and beta. IFNAR2 is also involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity. Following binding of IFNα2, IFNAR2 is internalized, but, instead of being routed towards degradation as it is when complexed to IFNβ, it recycles back to the cell surface.